Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Port Delivery System in wet AMD
NCT02510794Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2015
- Primary completion
- Apr 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in exudative macular degeneration, sponsored by Genentech. Started Sep 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02510794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510794.